Furthermore, Sj-Cys also mitigated sepsis-induced cardiomyopathy by inhibiting the lipopolysaccharides (LPS)-myeloid differentiation primary response 88 (MYD88) inflammatory signaling pathway and might have some therapeutic efficacy in the sepsis-associated cardiac dysfunction[25]. This evidence concerns the gene MYD88 and cardiomyopathy.